MX370664B - Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. - Google Patents

Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.

Info

Publication number
MX370664B
MX370664B MX2016002077A MX2016002077A MX370664B MX 370664 B MX370664 B MX 370664B MX 2016002077 A MX2016002077 A MX 2016002077A MX 2016002077 A MX2016002077 A MX 2016002077A MX 370664 B MX370664 B MX 370664B
Authority
MX
Mexico
Prior art keywords
grp94 inhibitors
selective grp94
compounds
effective amount
selective
Prior art date
Application number
MX2016002077A
Other languages
English (en)
Spanish (es)
Other versions
MX2016002077A (es
Inventor
Sun Weilin
Taldone Tony
Patel Pallav
Chiosis Gabriela
Yan Pengrong
J Patel Hardik
Yang Chenghua
O Ochiana Stefan
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2016002077A publication Critical patent/MX2016002077A/es
Publication of MX370664B publication Critical patent/MX370664B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Library & Information Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
MX2016002077A 2013-08-16 2014-08-15 Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. MX370664B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361866932P 2013-08-16 2013-08-16
PCT/US2014/051332 WO2015023976A2 (fr) 2013-08-16 2014-08-15 Inhibiteurs sélectifs de la grp94 et leurs utilisations

Publications (2)

Publication Number Publication Date
MX2016002077A MX2016002077A (es) 2016-07-21
MX370664B true MX370664B (es) 2019-12-19

Family

ID=52468819

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002077A MX370664B (es) 2013-08-16 2014-08-15 Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.

Country Status (17)

Country Link
US (3) US10421758B2 (fr)
EP (1) EP3033338A4 (fr)
JP (2) JP6539275B2 (fr)
KR (1) KR102319582B1 (fr)
CN (1) CN105899503B (fr)
AU (2) AU2014306417C1 (fr)
BR (1) BR112016003201A2 (fr)
CA (1) CA2921571C (fr)
EA (1) EA201690406A1 (fr)
HK (1) HK1226063A1 (fr)
IL (2) IL244251B (fr)
MX (1) MX370664B (fr)
PH (1) PH12016500511A1 (fr)
SG (2) SG10201801281QA (fr)
TW (1) TWI711618B (fr)
WO (1) WO2015023976A2 (fr)
ZA (1) ZA201601794B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2008005937A2 (fr) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES PAR L'INHIBITION DE Hsp90
LT2486039T (lt) 2009-10-07 2016-10-10 Sloan Kettering Institute For Cancer Research Purino dariniai, naudingi kaip hsp90 slopikliai
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
EP2694505B1 (fr) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Inhibiteurs de la hsp90
CN105637097A (zh) * 2013-08-05 2016-06-01 特韦斯特生物科学公司 从头合成的基因文库
BR112016003201A2 (pt) * 2013-08-16 2017-11-21 Memorial Sloan Kettering Cancer Center inibidores de grp94 seletivos e usos dos mesmos
TWI673279B (zh) 2013-12-23 2019-10-01 美國紀念斯隆-凱特琳癌症中心 用於放射性標記之方法及試劑
MA40535A (fr) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
MA47474A (fr) 2015-10-05 2019-12-25 Memorial Sloan Kettering Cancer Center Polythérapie rationelle pour le traitement du cancer
CN108503643B (zh) * 2017-02-28 2020-09-15 泉州易初生物医药科技有限公司 蛋白酶抑制剂的制备方法
CA3056797A1 (fr) * 2017-03-16 2018-09-20 Children's Medical Center Corporation Liposomes ingenierises utilises en tant qu'agents therapeutiques ciblant le cancer
US20200338084A1 (en) * 2018-01-02 2020-10-29 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
EP4163298A4 (fr) * 2020-06-09 2024-06-12 Kookmin University Industry Academy Cooperation Foundation Anticorps se liant de manière spécifique à grp94 ou un fragment de liaison à l'antigène de celui-ci, et utilisations associées
KR20230000050A (ko) 2021-06-24 2023-01-02 최현지 페이크 마스크
CN113663078B (zh) * 2021-06-28 2023-05-16 四川大学 Grp94抑制剂在制备治疗EGFR驱动的癌症的药物中的用途
KR20240012846A (ko) 2022-07-21 2024-01-30 성균관대학교산학협력단 신규한 hdac6 선택적 억제제 및 이의 용도
CN115717144A (zh) * 2022-08-25 2023-02-28 南通市肿瘤医院 抑制hsp90b1表达的小干扰rna及其在膀胱癌衰老中的应用
WO2024059745A2 (fr) * 2022-09-15 2024-03-21 Bexson Biomedical, Inc. Antagonistes du récepteur n-méthyl-d-aspartate (rnmda) et utilisations correspondantes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100341341B1 (ko) 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
KR100850727B1 (ko) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
EP1450784A4 (fr) 2001-11-09 2005-02-09 Conforma Therapeutics Corp Composes de zearalanol inhibant hsp90 et leurs procedes de production et d'utilisation
WO2005028434A2 (fr) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Nouveaux composes heterocycliques utilises en tant qu'inhibiteurs de la proteine hsp90
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP1962863A4 (fr) 2005-12-22 2010-11-24 Conforma Therapeutics Corp Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90
CA2652263A1 (fr) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Composes therapeutiques et leur utilisation contre le cancer
WO2008005937A2 (fr) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES PAR L'INHIBITION DE Hsp90
AU2007305166A1 (en) * 2006-10-03 2008-04-10 University Of Southern California GRP78 as a predictor of responsiveness to therapeutic agents
BRPI0808301B1 (pt) 2007-03-20 2022-05-03 Curis, Inc Composto e composição farmacêutica
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
WO2010042500A2 (fr) * 2008-10-06 2010-04-15 Emory University Inhibiteurs de la protéine de choc thermique 90, leurs procédés de préparation et leurs procédés d'utilisation
LT2486039T (lt) 2009-10-07 2016-10-10 Sloan Kettering Institute For Cancer Research Purino dariniai, naudingi kaip hsp90 slopikliai
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
EP2694505B1 (fr) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Inhibiteurs de la hsp90
US8685966B2 (en) * 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
EP2714081A4 (fr) 2011-05-27 2015-09-09 Cytocure Llc Méthodes, compositions et trousses pour le traitement du cancer
CN109374889B (zh) 2011-07-08 2022-04-19 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
BR112016003201A2 (pt) * 2013-08-16 2017-11-21 Memorial Sloan Kettering Cancer Center inibidores de grp94 seletivos e usos dos mesmos

Also Published As

Publication number Publication date
US11267816B2 (en) 2022-03-08
IL267681B (en) 2022-11-01
MX2016002077A (es) 2016-07-21
US20160194328A1 (en) 2016-07-07
BR112016003201A2 (pt) 2017-11-21
CA2921571C (fr) 2022-04-05
CA2921571A1 (fr) 2015-02-19
ZA201601794B (en) 2019-09-25
AU2019202669B2 (en) 2020-12-03
IL267681A (en) 2019-08-29
SG11201601542SA (en) 2016-04-28
SG10201801281QA (en) 2018-04-27
CN105899503A (zh) 2016-08-24
WO2015023976A3 (fr) 2015-04-23
AU2014306417B2 (en) 2019-01-17
AU2019202669A1 (en) 2019-05-09
JP2016533384A (ja) 2016-10-27
HK1226063A1 (zh) 2017-09-22
KR20160043534A (ko) 2016-04-21
IL244251B (en) 2019-07-31
CN105899503B (zh) 2020-08-18
US20200102312A1 (en) 2020-04-02
EP3033338A2 (fr) 2016-06-22
KR102319582B1 (ko) 2021-11-04
JP6539275B2 (ja) 2019-07-03
US20230123747A1 (en) 2023-04-20
EA201690406A1 (ru) 2016-08-31
AU2014306417A1 (en) 2016-03-17
JP2019178147A (ja) 2019-10-17
IL267681B2 (en) 2023-03-01
JP6848009B2 (ja) 2021-03-24
TWI711618B (zh) 2020-12-01
TW201516047A (zh) 2015-05-01
WO2015023976A2 (fr) 2015-02-19
US10421758B2 (en) 2019-09-24
IL244251A0 (en) 2016-04-21
PH12016500511A1 (en) 2016-06-13
AU2014306417C1 (en) 2019-07-25
EP3033338A4 (fr) 2017-06-14

Similar Documents

Publication Publication Date Title
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2019002259A (es) Inhibicion de la actividad de la olig2.
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
AU2014353885A8 (en) Prevention and treatment of toxicosis
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12020500472A1 (en) Autotaxin inhibitor compounds
EA201691907A1 (ru) Комбинированная терапия кураксинами

Legal Events

Date Code Title Description
FG Grant or registration